메뉴 건너뛰기




Volumn 29, Issue 7, 2011, Pages 797-804

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERCELLULAR ADHESION MOLECULE 1; MELPHALAN; PREDNISOLONE; PROTEIN PPARD; PROTEIN SERPINB2; PROTEIN SLC12A6; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

EID: 79952322815     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.0792     Document Type: Article
Times cited : (96)

References (42)
  • 2
    • 0033918032 scopus 로고    scopus 로고
    • Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
    • Zomas A, Anagnostopoulos N, Dimopoulos MA: Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 25:1319-1320, 2000 (Pubitemid 30428151)
    • (2000) Bone Marrow Transplantation , vol.25 , Issue.12 , pp. 1319-1320
    • Zomas, A.1    Anagnostopoulos, N.2    Dimopoulos, M.A.3
  • 4
    • 33751094293 scopus 로고    scopus 로고
    • The troublesome toxicity of peripheral neuropathy with thalidomide
    • DOI 10.1080/10428190600948303, PII M867836022V65854
    • Mileshkin L, Prince HM: The troublesome toxicity of peripheral neuropathy with thalidomide. Leuk Lymphoma 47:2276-2279, 2006 (Pubitemid 44768418)
    • (2006) Leukemia and Lymphoma , vol.47 , Issue.11 , pp. 2276-2279
    • Mileshkin, L.1    Prince, H.M.2
  • 8
    • 0005185331 scopus 로고
    • Low serum vitamin B12 in patients with plasma cell myeloma is associated with plasma cell myeloma with true functional cobalamin deficiency
    • Beckmann MJ, Hussein MA, Lichtin A, et al: Low serum vitamin B12 in patients with plasma cell myeloma is associated with plasma cell myeloma with true functional cobalamin deficiency. Am J Clin Pathol 140:350, 1995
    • (1995) Am J Clin Pathol , vol.140 , pp. 350
    • Beckmann, M.J.1    Hussein, M.A.2    Lichtin, A.3
  • 9
    • 0034745883 scopus 로고    scopus 로고
    • Thalomid (thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing
    • Clark TE, Edom N, Larson J, et al: Thalomid (thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 24:87-117, 2001
    • (2001) Drug Saf , vol.24 , pp. 87-117
    • Clark, T.E.1    Edom, N.2    Larson, J.3
  • 10
    • 12244249165 scopus 로고    scopus 로고
    • Thalidomide-induced neuropathy: A ganglionopathy?
    • Giannini F, Volpi N, Rossi S, et al: Thalidomide-induced neuropathy: A ganglionopathy? Neurology 60:877-878, 2003
    • (2003) Neurology , vol.60 , pp. 877-878
    • Giannini, F.1    Volpi, N.2    Rossi, S.3
  • 11
    • 0343628805 scopus 로고    scopus 로고
    • Thalidomide neuropathy: Role of F-wave monitoring
    • DOI 10.1002/1097-4598(200008)23:8<1301::AID-MUS25>3.0.CO;2-4
    • Rao DG, Kane NM, Oware A: Thalidomide neuropathy: Role of F-wave monitoring. Muscle Nerve 23:1301-1302, 2000 (Pubitemid 30602257)
    • (2000) Muscle and Nerve , vol.23 , Issue.8 , pp. 1301-1302
    • Ganesh, R.D.1    Kane, N.M.2    Oware, A.3
  • 12
    • 0022649529 scopus 로고
    • Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation
    • Hess CW, Hunziker T, Küpfer A, et al: Thalidomide-induced peripheral neuropathy: A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 233:83-89, 1986 (Pubitemid 16125225)
    • (1986) Journal of Neurology , vol.233 , Issue.2 , pp. 83-89
    • Hess, C.W.1    Hunziker, T.2    Kupfer, A.3    Ludin, H.P.4
  • 13
    • 0028879821 scopus 로고
    • Thalidomide-induced neuropathy and genetic differences in drug metabolism
    • Harland CC, Steventon GB, Marsden JR: Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 49:1-6, 1995
    • (1995) Eur J Clin Pharmacol , vol.49 , pp. 1-6
    • Harland, C.C.1    Steventon, G.B.2    Marsden, J.R.3
  • 14
    • 52449099461 scopus 로고    scopus 로고
    • Genomic variation in myeloma: Design, content, and initial application of the Bank on A Cure SNP Panel to detect associations with progression-free survival
    • Van Ness B, Ramos C, Haznadar M, et al: Genomic variation in myeloma: Design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 6:26, 2008
    • (2008) BMC Med , vol.6 , pp. 26
    • Van Ness, B.1    Ramos, C.2    Haznadar, M.3
  • 15
    • 58149380751 scopus 로고    scopus 로고
    • Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
    • Johnson DC, Corthals S, Ramos C, et al: Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 112:4924-4934, 2008
    • (2008) Blood , vol.112 , pp. 4924-4934
    • Johnson, D.C.1    Corthals, S.2    Ramos, C.3
  • 16
    • 70350092339 scopus 로고    scopus 로고
    • Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
    • Durie BG, Van Ness B, Ramos C, et al: Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma. Leukemia 23:1913-1919, 2009
    • (2009) Leukemia , vol.23 , pp. 1913-1919
    • Durie, B.G.1    Van Ness, B.2    Ramos, C.3
  • 18
    • 0038005018 scopus 로고    scopus 로고
    • DAVID: Database for Annotation, Visualization, and Integrated Discovery
    • Dennis G Jr, Sherman BT, Hosack DA, et al: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4:P3, 2003
    • (2003) Genome Biol , vol.4 , pp. 3
    • Dennis Jr., G.1    Sherman, B.T.2    Hosack, D.A.3
  • 20
    • 33748190743 scopus 로고    scopus 로고
    • Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
    • DOI 10.1182/blood-2006-02-005496
    • Walker BA, Leone PE, Jenner MW, et al: Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108:1733-1743, 2006 (Pubitemid 44316144)
    • (2006) Blood , vol.108 , Issue.5 , pp. 1733-1743
    • Walker, B.A.1    Leone, P.E.2    Jenner, M.W.3    Li, C.4    Gonzalez, D.5    Johnson, D.C.6    Ross, F.M.7    Davies, F.E.8    Morgan, G.J.9
  • 21
    • 27644482314 scopus 로고    scopus 로고
    • Mapping determinants of human gene expression by regional and genome-wide association
    • DOI 10.1038/nature04244, PII N04244
    • Cheung VG, Spielman RS, Ewens KG, et al: Mapping determinants of human gene expression by regional and genome-wide association. Nature 437:1365-1369, 2005 (Pubitemid 41568683)
    • (2005) Nature , vol.437 , Issue.7063 , pp. 1365-1369
    • Cheung, V.G.1    Spielman, R.S.2    Ewens, K.G.3    Weber, T.M.4    Morley, M.5    Burdick, J.T.6
  • 22
    • 65849256988 scopus 로고    scopus 로고
    • Willows: A memory efficient tree and forest construction package
    • Zhang H, Wang M, Chen X: Willows: A memory efficient tree and forest construction package. BMC Bioinformatics 10:130, 2009
    • (2009) BMC Bioinformatics , vol.10 , pp. 130
    • Zhang, H.1    Wang, M.2    Chen, X.3
  • 23
    • 0036517472 scopus 로고    scopus 로고
    • A comprehensive review of genetic association studies
    • Hirschhorn JN, Lohmueller K, Byrne E, et al: A comprehensive review of genetic association studies. Genet Med 4:45-61, 2002
    • (2002) Genet Med , vol.4 , pp. 45-61
    • Hirschhorn, J.N.1    Lohmueller, K.2    Byrne, E.3
  • 24
    • 77949756362 scopus 로고    scopus 로고
    • Genome-wide association studies in pharmacogenomics
    • Daly AK: Genome-wide association studies in pharmacogenomics. Nat Rev Genet 11:241-246, 2010
    • (2010) Nat Rev Genet , vol.11 , pp. 241-246
    • Daly, A.K.1
  • 27
  • 29
    • 33846504706 scopus 로고    scopus 로고
    • A "silent" polymorphism in the MDR1 gene changes substrate specificity
    • Kimchi-Sarfaty C, Oh JM, Kim IW, et al: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528, 2007
    • (2007) Science , vol.315 , pp. 525-528
    • Kimchi-Sarfaty, C.1    Oh, J.M.2    Kim, I.W.3
  • 30
    • 51649129871 scopus 로고    scopus 로고
    • ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel
    • Sissung TM, Baum CE, Deeken J, et al: ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14:4543-4549, 2008
    • (2008) Clin Cancer Res , vol.14 , pp. 4543-4549
    • Sissung, T.M.1    Baum, C.E.2    Deeken, J.3
  • 32
    • 33749028208 scopus 로고    scopus 로고
    • A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor
    • Yang XX, Hu ZP, Xu AL, et al: A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. J Pharmacol Exp Ther 319:82-104, 2006
    • (2006) J Pharmacol Exp Ther , vol.319 , pp. 82-104
    • Yang, X.X.1    Hu, Z.P.2    Xu, A.L.3
  • 34
    • 0037974540 scopus 로고    scopus 로고
    • Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide
    • Ando Y, Price DK, Dahut WL, et al: Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 1:669-673, 2002
    • (2002) Cancer Biol Ther , vol.1 , pp. 669-673
    • Ando, Y.1    Price, D.K.2    Dahut, W.L.3
  • 35
    • 0036285336 scopus 로고    scopus 로고
    • Thalidomide metabolism by the CYP2C subfamily
    • Ando Y, Fuse E, Figg WD: Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973, 2002
    • (2002) Clin Cancer Res , vol.8 , pp. 1964-1973
    • Ando, Y.1    Fuse, E.2    Figg, W.D.3
  • 36
    • 36348965389 scopus 로고    scopus 로고
    • Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma
    • DOI 10.3324/haematol.11319
    • Li Y, Hou J, Jiang H, et al: Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica 92:1246-1249, 2007 (Pubitemid 350144185)
    • (2007) Haematologica , vol.92 , Issue.9 , pp. 1246-1249
    • Li, Y.1    Hou, J.2    Jiang, H.3    Wang, D.4    Fu, W.5    Yuan, Z.6    Chen, Y.7    Zhou, L.8
  • 38
    • 0037083631 scopus 로고    scopus 로고
    • Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth
    • Bonilla IE, Tanabe K, Strittmatter SM: Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. J Neurosci 22:1303-1315, 2002 (Pubitemid 34163732)
    • (2002) Journal of Neuroscience , vol.22 , Issue.4 , pp. 1303-1315
    • Bonilla, I.E.1    Tanabe, K.2    Strittmatter, S.M.3
  • 39
    • 15044339715 scopus 로고    scopus 로고
    • Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury
    • DOI 10.1016/j.neuroscience.2004.12.003
    • Yamanaka H, Obata K, Fukuoka T, et al: Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury. Neuroscience 132:183-191, 2005 (Pubitemid 40380725)
    • (2005) Neuroscience , vol.132 , Issue.1 , pp. 183-191
    • Yamanaka, H.1    Obata, K.2    Fukuoka, T.3    Dai, Y.4    Kobayashi, K.5    Tokunaga, A.6    Noguchi, K.7
  • 40
    • 67650698311 scopus 로고    scopus 로고
    • A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma
    • Kodama T, Abe M, Iida S, et al: A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. Clin Lymphoma Myeloma 9:154-159, 2009
    • (2009) Clin Lymphoma Myeloma , vol.9 , pp. 154-159
    • Kodama, T.1    Abe, M.2    Iida, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.